Aravive PROC readout ‘not getting enough attention,’ says Cantor Fitzgerald

Cantor Fitzgerald notes that Aravive will report topline results for its Phase 3 AXLerateOC trial of batiraxcept plus paclitaxel in platinum resistant ovarian cancer, or PROC, patients likely in August and argues that “this important potential catalyst for the stock is not getting enough attention.” The firm, which thinks that the risk reward into this readout is positive and that peak sales potential for lead product candidate batiraxcept “remains underappreciated,” keeps an Overweight rating and $18 price target on Aravive shares.